心房颤动治疗新循证医学证据-英文_第1页
心房颤动治疗新循证医学证据-英文_第2页
心房颤动治疗新循证医学证据-英文_第3页
心房颤动治疗新循证医学证据-英文_第4页
心房颤动治疗新循证医学证据-英文_第5页
已阅读5页,还剩28页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、心房颤动治疗新循证医学证据英文Prevalence of AF is increasingAdults with AFib (millions)Year2.082.262.442.662.943.333.804.784.345.165.425.61%363753YearProportion Aged 80 YrGo: JAMA, 2001:2370Miyasaka.Circulation.2006:119Year2.04.06.08.010.012.014.016.020002005201020152020202520302035204020452050Adults with AFib (mi

2、llions)5.110.28.412.115.9Prevalence of AF is increasingPrevalence %AgePrevalence of AF:the Rotterdam studyHeerinaga.Eur Heart J,2006,9496808 pts., F/U 6.9 yrs,prevalence 5.5%Incidence AgeIncidence of AF:the Rotterdam studyHeerinaga.Eur Heart J,2006,9496808 pts., F/U 6.9 yrs,Incidence 9.9Identified A

3、F:the tip of the iceberg14802 pts aged 65 or over,randomized to systemic screening and opportunistic screening Systemic screening group:9866 pts. Opportunistic screening group: 4936 pts.F/U 12 mons Rate of new AF case in systemic screening 1.63%, Rate of new AF case in opportunistic screening 1.04%F

4、itzmaurice.BMJ.2007,383Risk for stroke increased in lone AFJahangir. Circulation. 2007:3050Meta-analysis:antithrombotic therapy of AFHart.Ann Intern Med,2007,857trialptsRR reduced(%)Warfarin vs Placebo6290064ASA vs Placebo8487622Warfarin vs ASA121296339Real world of warfarin in the elderly13.1%4.7%T

5、he first 90 days associated with major hemorrhage21% pts withdrawn warfarin for safety issueThe higher risk of stroke, the higher incidence of major hemorrhageHylek. Circulation.2007,2689 HR for ICH was 4.06 for AsiansAsians were at greater risk for warfarin-ralated ICHShen. JACC.2007:309 Prospectiv

6、e,randomize,control973 pts 75 years old with AFRandomized into warfarin arm (INR 2.0-3.0) and Aspirin arm(75mg/d)Mean F/U 2.7 yrsPrimary outcome:fatal or disabling stroke, intracranial haemorrhage, or arterial embolismWarfarin versus aspirin for stroke prevention in the elderly with AF(The Birmingha

7、m Atrial Fibrillation Treatment of the Aged Study,BAFTA study)Mant.Lancet,2007,4930.831.155(0.4%)6(0.5%) haemorrhagic0.651.921(0.1%)2(0.2%)Other ICH0.360.323(0.2%)1(0.1%)Embolism48(3.8%)7(0.5%)32(2.5%)23(1.8%)21(1.6%)44(3.4%)0.0050.338(0.6%) disabling nonfatal0.00270.4824(1.8%)Total0.530.695(0.4%) u

8、nknown0.00040.3010(0.8%) ischemic0.140.5913(1.0%) fatal0.0030.4621(1.6%)StrokepEventwarfarin(n=488)ASA(n=488)N(Risk peryear)N(Risk peryear)warfarinVS.ASARRWarfarin versus aspirin for stroke prevention in the elderly with AFMant.Lancet,2007,493Mant.Lancet,2007,493Warfarin versus aspirin for stroke pr

9、evention in the elderly with AFAnticoagulation in clinical practice2.03/100person-yrs1.17/100person-yrs11,526 pts with AF,54.8% was on warfarinRelative risk for thromb -embolism reduced 51% in warfarin therapyThe intracranial hemorrhage rate increased in warfarin(0.46/100 person-yrs VS 0.23/100 pers

10、on-yrs)Warfarin was not associated with nonintracranial hemorrhage (1.05/100 person-yrs VS 1.06/100 person-yrs)Go.JAMA 2003:2685RivaroxabanEnoxaparin873 ptsEndpoints included DVT,PE,all cause mortality Safety:major hemorrhageEndpointsSafetyEriksson. Circulation. 2006: 2374%Rivaroxaban New promise of

11、 anticoagulation?Prospective RIKS-HIA60764 pts,AF 21459 pts,CHF 22345 pts,AF+CHF16960 ptsF/U 1 yrHigher mortality rate in AF without CHF pts taking digoxin (RR1.42)Similar mortality rate in CHF or AF+CHF pts with or without digoxin Digoxin and mortality in AF:A prospective cohort studyHallberg.Euro

12、J Clin Pharmacol,2007,959Hallberg.Euro J Clin Pharmacol,2007,959Digoxin and mortality in AF:A prospective cohort studyAdverse effects of oral amiodaroneZimetbaum.NEJM.2007:935Bradycardia5%Prolonged QT In mostTdp1%Hepatic15%Hyperthyroidism3%Hypothyroidism20%Pulmonary3%Dermatology25-75%Neurologic3-30%

13、Corneal deposits100%Optic neuritis AAD:4%Catheter ablation decrease the incidence of stroke755 ptsThe incidence of stroke/TIA was 1.1%0.9% occurred whithin 2 weeks of RFCA79% of pts without risk factor for stroke and 68% of pts with 1 risk factor in sinus discontinued warfarinPatients with sinus rhy

14、thm was thromboembolic event free after the procedureOral.Circulation.2006:759Pappone . JACC.2003:185N=589N=582Catheter ablation reduce strokePappone . JACC.2003:185Catheter ablation improve prognosisNo risk factor: ASA 81- 325mg One moderate risk factor:ASA 81- 325mg or warfarinAny high risk factor

15、 or more than one moderate risk factor: warfarinPrinciples of anticoagulationAmiodaroneAblation !No OHD yesHTN yes(concomitanc with LVH amiodaroneablation )CAD yesHF amiodaroneablation Maintain Sinus RhythmCatheter ablation is a reasonablealternative topharmacological therapy to prevent recurrentAF

16、(IIa,C)Fuster. Circulation.2006 :e257 Indications for catheter ablationThe presence of symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medicationin rare clinical situations, it may be appropriate to perform catheter ablation of AF as first line therapyselected symptomatic patients with heart failure and/or reduced ejection fractionLA thrombus is a contraindicationHRS/EHRA/ECAS Expert Consensus StatementAF Ablation as first-line therapy?(Catheter Ablation vs. Antiarrhythmic Drug Therapyfor Atrial Fibr

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论